
Please try another search
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Name | Age | Since | Title |
---|---|---|---|
Susan Shiff | - | 2025 | Director |
Keith T. Flaherty | 54 | - | Scientific Advisory Board Member |
Imran Alibhai | - | - | CEO & Director |
Sujal Arun Shah | 52 | 2021 | Chairman |
Wallace Hall | - | - | Founder, President & Director |
Jeff Swigris | - | 2024 | Scientific Advisory Board Member |
David J. Tweardy | - | 2017 | Co-Founder & Scientific Advisory Board Member |
Ronald A. DePinho | 70 | 2017 | Co-Founder & Chairman of Scientific Advisory Board |
Michael T. Lewis | - | - | Co-Founder & Scientific Advisory Board Member |
Michael Stephen Wyzga | 70 | 2021 | Independent Director |
Cynthia Smith | 56 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review